Rosanna Tarricone1, Dana Abu Koush2, Barbara Nyanzi-Wakholi3, Antonieta Medina-Lara4. 1. Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy; Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy. 2. Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy. 3. Independent Consultant, Kampala, Uganda. 4. Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy; Health Economics Group, University of Exeter Medical School, Exeter, UK. Electronic address: A.Medina-Lara@exeter.ac.uk.
Abstract
INTRODUCTION: Chemotherapy-induced diarrhea (CID) diminishes physical performance, raises anxiety and depression levels, and increases healthcare resource utilization. OBJECTIVE: To understand the impact that CID has on health-related quality of life (HRQoL) and on healthcare resource utilization. METHODS: Systematic searches were conducted in MEDLINE, EMBASE, DARE, and the NHS EED databases. RESULTS: A total of 22 articles were retrieved for full review (n=17, HRQoL; n=5 healthcare resource utilization). Only 2 studies had assessed HRQoL in patients experiencing CID, while cost studies demonstrated that CID episodes are unnecessarily expensive and can be avoided if diagnosed and treated early. CONCLUSIONS: Better management of CID has the potential to reduce overall economic burden and improve patients' HRQoL. Available evidence also relays the need to conduct larger studies that assess HRQoL and consider cost beyond direct medical costs in order to understand the full impact of CID on HRQoL and healthcare resource utilization. Crown
INTRODUCTION: Chemotherapy-induced diarrhea (CID) diminishes physical performance, raises anxiety and depression levels, and increases healthcare resource utilization. OBJECTIVE: To understand the impact that CID has on health-related quality of life (HRQoL) and on healthcare resource utilization. METHODS: Systematic searches were conducted in MEDLINE, EMBASE, DARE, and the NHS EED databases. RESULTS: A total of 22 articles were retrieved for full review (n=17, HRQoL; n=5 healthcare resource utilization). Only 2 studies had assessed HRQoL in patients experiencing CID, while cost studies demonstrated that CID episodes are unnecessarily expensive and can be avoided if diagnosed and treated early. CONCLUSIONS: Better management of CID has the potential to reduce overall economic burden and improve patients' HRQoL. Available evidence also relays the need to conduct larger studies that assess HRQoL and consider cost beyond direct medical costs in order to understand the full impact of CID on HRQoL and healthcare resource utilization. Crown
Authors: Amber S Kleckner; Ian R Kleckner; Charles S Kamen; Mohamedtaki A Tejani; Michelle C Janelsins; Gary R Morrow; Luke J Peppone Journal: Ther Adv Med Oncol Date: 2019-08-01 Impact factor: 8.168
Authors: Helena Harder; Valerie M Shilling; Shirley F May; David Cella; Peter Schmid; Lesley J Fallowfield Journal: Breast Cancer Res Treat Date: 2020-07-27 Impact factor: 4.872